HAMLET successful human trials featured in South China Morning Post
Following the successful human trial of the HAMLET drug candidate Alpha1H and publication of the results in Nature Communications, Hamlet Pharma and its founder Catharina Svanborg are the topic of an in-depth feature in South China Morning Post's Health & Wellness section, published on July 5[th]. South China Morning Post is Hong Kong-based and has a circulation of 105 000 with 197 million page views per month.“We are pleased and very excited. It takes a dedicated team and very hard work to a discovery all the way to the clinic. It is wonderful to see beneficial effects for the cancer